REDWOOD CITY, CA – September 21, 2016 – PaxVax today announced its President and CEO, Nima Farzan, has been invited to join the interim board of the Coalition for Epidemic Preparedness Innovations (CEPI) as the Biotechnology Innovation Organization (BIO) delegate. CEPI is a new, public-private alliance designed to speed the development of new vaccines to prevent and contain global epidemics. Sparked by recent gaps in vaccine preparedness for outbreaks of Zika and Ebola, CEPI aims to facilitate the creation of an arsenal of vaccines to prevent diseases such as these from becoming public health emergencies in the future.
“PaxVax is committed to developing and delivering vaccines that address global public health threats. In joining the CEPI leadership, I look forward to continue pursuing innovative efforts aimed to prepare against future pandemics,” said Farzan. “As biotech companies have both the expertise and responsibility to take part in this cause, I am thrilled to join CEPI’s visionary team of experts in the global fight to protect against infectious diseases.”
CEPI was founded by the Wellcome Trust, the Bill and Melinda Gates Foundation, the World Economic Forum and the governments of Norway and India. The organization will finance, coordinate and facilitate the development of vaccines for potential global threats before outbreaks begin. Farzan joins CEPI’s board of global leaders from academia, government, non-profits and industry, gathered to shape an informed, collaborative approach to ensure vaccines are available for all populations who need them.
“We have seen in recent outbreaks that when working alone, industry players face barriers to vaccine development,” Farzan said. “CEPI’s collaborative approach is vital in taking on global health threats. I am proud to serve on its board among leaders forging a unified response to pandemics.”
Farzan has been President and CEO of PaxVax since 2015 and previously served as Chief Operating Officer from 2011. He has extensive biopharmaceutical experience, most recently providing leadership at PaxVax in the advancement of a vaccine for cholera from research and development through to approval by the U.S. Food and Drug Administration.
PaxVax develops, manufactures and commercializes innovative specialty vaccines against infectious diseases present and emerging in the developing world. PaxVax has licensed vaccines for typhoid fever (Vivotif®) and cholera (Vaxchora™), and vaccines at various stages of research and clinical development for adenovirus, anthrax, hepatitis A, HIV, and Zika. PaxVax is focused on traditionally overlooked markets such as travel, and as part of its social mission, PaxVax is also working to make its vaccines available to broader populations most affected by these diseases. PaxVax is headquartered in Redwood City, California and maintains research and development and Good Manufacturing Practice (GMP) facilities in San Diego, California and Bern, Switzerland and other operations in Bermuda and Europe. More information is available at www.PaxVax.com.
Phase One Study of Oral Replicating Vaccine for H5N1 Published in Lancet Infectious Diseases
Menlo Park, Calif., – January 31, 2013 – PaxVax, Inc., which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced positive results in a Phase 1 clinical trial for its oral, replicating adenovirus serotype 4 (Ad4) vector vaccine for H5N1 (avian flu). The results have been published in the journal Lancet Infectious Diseases (published online January 29, 2013). The study was funded by The Wellcome Trust.
Vaccine Candidate Found to be Well Tolerated and Immunogenic
Menlo Park, Calif., and Atlanta – November 14, 2012 – PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner today announced results from a Phase 1 clinical trial of PaxVax’s single-dose oral cholera vaccine candidate at the 2012 American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting in Atlanta. The results were presented by the company’s collaborator, Dr. Wilbur Chen of the University of Maryland, Baltimore. The vaccine candidate, PXVX0200 (also known as CVD 103-HgR), was found to be well tolerated and immunogenic.
Company to Begin Phase 3 Trials for First Cholera Vaccine Candidate in U.S.
Menlo Park, Calif. – March 19, 2012 – PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for its single-dose oral cholera vaccine, clearing the way to begin clinical trials. The company intends to begin Phase 3 trials later this year.
Accomplished Vaccine Industry Executives Appointed to COO, CTO, and CSO Positions
Menlo Park, Calif. – February 9, 2012 – PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced the expansion of its executive management team with the appointments of Nima Farzan as Executive Vice President and Chief Operating Officer, Thomas P. Monath, M.D. as Chief Technology Officer, and Jonathan F. Smith, Ph.D. as Executive Vice President and Chief Scientific Officer.